At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
PF-07202954 Repeat Dose +2 moredrug
Likely dose
PF-07202954 Repeat Dose 1200 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, 3-PART, SPONSOR OPEN STUDY OF PF-07202954 IN HEALTHY ADULTS: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE (IN PART 1), AND REPEATED (IN PART 2), ESCALATING, ORAL DOSES ALONG WITH CONDITIONAL PART 3 OF RANDOMIZED, OPEN-LABEL ASSESSMENT OF EFFECT OF FOOD ON PF-07202954 EXPOSURE
In Brief
A Phase 1 clinical trial evaluating PF-07202954 Repeat Dose, PF-07202954 Single Dose, and 1 other intervention for Non-Alcoholic Fatty Liver Disease and Liver Fibrosis. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The study is planned as a 3 part design with investigator and participant blinded (sponsor-open), placebo controlled, randomized, dose escalation in Part 1 and Part 2; and a randomized, open label design, in Part 3 (if conducted).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Alcoholic Fatty Liver Disease, Liver Fibrosis
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartMay 2021
Primary CompletionSep 2021
TodayJul 2026
First PostedApr 23, 2021
Enrollment StartMay 13, 2021
Primary CompletionSep 17, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.2 years ago
Interventions
PF-07202954 Repeat Dosedrug
10, 30, 100, 300, 600, 1200 milligrams (mg)
PF-07202954 Single Dosedrug
10, 30, 100, 300, 600, 900, 1200 milligrams (mg)
Placebodrug
Matching Placebo